Citadel Advisors
KBIO

Citadel Advisors’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Citadel Advisors’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,261
Closed -$16K – 9144
2014
Q3 		$16K Buy
+1,261
New +$17.4K ﹤0.01% 7603

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.45B AUM 5.8% 1-Year Est. Return

Citadel Advisors's KBIO Position: Q4 2014 in Review

Citadel Advisors sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2014, closing a stake of 1,261 shares — an estimated $16K sold.

Citadel Advisors first reported a position in KBIO in Q3 2014 and held it in 1 quarter. The position peaked at $16K in Q3 2014. 36 funds tracked by Wall St. Rank hold KBIO as of Q4 2014.

  • Citadel Advisors reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2014 after selling out during the quarter.
  • Citadel Advisors sold 1,261 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2014, an estimated $16K.
  • Citadel Advisors first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q3 2014 and held it in 1 quarter.
  • Citadel Advisors's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $16K in Q3 2014.
  • 36 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2014.

Based on Citadel Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.